Moderate uptake levels (average SUVmax 5–10) were observed in human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC), gynecological tumors, esophageal cancer, NSCLC, urothelial cancer, nasopharyngeal carcinoma (NPC), and head and neck cancer. Here, ERBB2 is linked to breast carcinoma.